Literature DB >> 219036

Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol.

R J Moore, J M Gazak, J D Wilson.   

Abstract

17 beta-estradiol enchances androgen-induced prostate growth in the castrate dog to a degree comparable to that seen in spontaneous prostatic hypertrophy. To investigate the mechanism of this synergism, cytosol androgen binding was measured by a density gradient technique in prostates of control and 17 beta-estradiol-treated castrate dogs. [3H]Dihydrotestosterone was bound principally to a moiety that averaged 8.6S in size. Approximately twofold enhancement of this binding by 17 beta-estradiol was demonstrable after 1 wk of treatment with 750 microgram/wk and after 3 wk with 75 microgram/wk. Under conditions in which binding in the 8S region was demonstrable with dihydrotestosterone and testosterone no binding of 3 alpha-androstanediol or progesterone was detectable. Thus, enhancement by 17 beta-estradiol of a prostate cytosol androgen-binding protein occurs under circumstances in which 17 beta-estradiol enhances androgen-mediated prostatic growth.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 219036      PMCID: PMC371961          DOI: 10.1172/JCI109310

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  A method for determining the sedimentation behavior of enzymes: application to protein mixtures.

Authors:  R G MARTIN; B N AMES
Journal:  J Biol Chem       Date:  1961-05       Impact factor: 5.157

2.  Induction and extinction of mammary cancer. A striking effect of hydrocarbons permits analysis of mechanisms of causes and cure of breast cancer.

Authors:  C HUGGINS; N C YANG
Journal:  Science       Date:  1962-07-27       Impact factor: 47.728

3.  Effect of stilboestrol on the prostate gland in normal puppies and adult dogs.

Authors:  O A BERG
Journal:  Acta Endocrinol (Copenh)       Date:  1958-02

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Progesterone and progesterone receptors in experimental breast cancer.

Authors:  K B Horwitz; W L McGuire
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

6.  Studies on the mechanism of 3 alpha-androstanediol-induced growth of the dog prostate.

Authors:  G H Jacobi; R J Moore; J D Wilson
Journal:  Endocrinology       Date:  1978-06       Impact factor: 4.736

7.  Comparative binding specificity of methyltrienolone in human and rat prostate.

Authors:  J Y Dubé; P Chapdelaine; R R Tremblay; C Bonne; J P Raynaud
Journal:  Horm Res       Date:  1976

8.  Formation of 5alpha-androstane-3alpha,17beta-diol by normal and hypertrophic human prostate.

Authors:  G H Jacobi; J D Wilson
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

9.  Characterization of the binding of a potent synthetic androgen, methyltrienolone, to human tissues.

Authors:  M Menon; C E Tananis; L L Hicks; E F Hawkins; M G McLoughlin; P C Walsh
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

10.  Demonstration of a progestin receptor in human benign prostatic hyperplasia and prostatic carcinoma.

Authors:  J A Gustafsson; P Ekman; A Pousette; M Snochowski; B Högberg
Journal:  Invest Urol       Date:  1978-03
View more
  14 in total

Review 1.  Review of current and future approaches to the management of benign prostatic hyperplasia.

Authors:  J C Gingell
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

Review 2.  Prostate gland: structure, functions and regulation.

Authors:  V L Kumar; P K Majumder
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

3.  Concentration of dihydrotestosterone and 3 alpha-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog.

Authors:  R J Moore; J M Gazak; J F Quebbeman; J D Wilson
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

Review 4.  Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.

Authors:  F Labrie; A Dupont; A Bélanger; L Cusan; M Giguère; Y Lacourcière; I Luthy; D Bégin; C Labrie; J Simard
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 5.  Age-dependent and gender-dependent regulation of hypothalamic-adrenocorticotropic-adrenal axis.

Authors:  Johannes D Veldhuis; Animesh Sharma; Ferdinand Roelfsema
Journal:  Endocrinol Metab Clin North Am       Date:  2013-03-13       Impact factor: 4.741

Review 6.  Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk.

Authors:  Mitchell S Steiner; Sharan Raghow
Journal:  World J Urol       Date:  2003-02-14       Impact factor: 4.226

7.  Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH.

Authors:  G Tolis; M Koutsilieris; R Herrera; A Stellos; A Martinez; M Dufresne
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

8.  Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.

Authors:  J Trachtenberg; L L Hicks; P C Walsh
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

9.  Alteration in the metabolism of dihydrotestosterone in elderly men with prostate hyperplasia.

Authors:  I Morimoto; A Edmiston; R Horton
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

10.  Changes in amount and intracellular distribution of androgen receptor in human foreskin as a function of age.

Authors:  C G Roehrborn; J L Lange; F W George; J D Wilson
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.